Pfizer And Valneva Announce Primary Vaccination Series Completion In Phase 3 VALOR Lyme Disease Trial; Participants Completed Primary Vaccination Series (3 Doses) With VLA15
Pfizer And Valneva Announce Primary Vaccination Series Completion In Phase 3 VALOR Lyme Disease Trial; Participants Completed Primary Vaccination Series (3 Doses) With VLA15
辉瑞和瓦尔内瓦宣布VALOR莱姆病三期试验的主要接种完成；参与者已完成3剂VLA15的主要接种
-
Participants completed primary vaccination series (3 doses) with VLA15
- Primary vaccination series to be followed by a booster approximately one year after completion
- 参与者完成了生物-疫苗VLA15的初级接种计划（3剂）。
- 初级接种计划完成后，应在约一年后进行一次加强针。
New York, NY and Saint-Herblain (France), July 17, 2024 – Pfizer Inc. (NYSE:PFE) and Valneva SE (NASDAQ:VALN, PARIS:VLA) today announced that the participants of the Phase 3 trial "Vaccine Against Lyme for Outdoor Recreationists" (VALOR) have completed the primary vaccination series (three doses) of Lyme disease vaccine candidate VLA15. Participants will be monitored for the occurrence of Lyme disease cases until the end of the Lyme disease season in 2025.1,
纽交所(PFE)和Valneva SE(纳斯达克:VALN，巴黎:VLA)今天宣布，第三期试验“针对户外运动爱好者的莱姆病疫苗”(VALOR)的参与者完成了莱姆病疫苗候选物VLA15的初级接种计划（三剂）。参与者将在2025年莱姆病季节结束前受监测，以了解莱姆病的发生情况。1